915 related articles for article (PubMed ID: 31892219)
1. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
Hughes-Parry HE; Cross RS; Jenkins MR
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
[TBL] [Abstract][Full Text] [Related]
2. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
3. Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting.
Sutherland AR; Owens MN; Geyer CR
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33007850
[TBL] [Abstract][Full Text] [Related]
4. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.
Abbott RC; Cross RS; Jenkins MR
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
8. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
9. CAR-Ts: new perspectives in cancer therapy.
Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
[TBL] [Abstract][Full Text] [Related]
10. Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors.
Lee YG; Marks I; Srinivasarao M; Kanduluru AK; Mahalingam SM; Liu X; Chu H; Low PS
Cancer Res; 2019 Jan; 79(2):387-396. PubMed ID: 30482775
[TBL] [Abstract][Full Text] [Related]
11. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
12. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
13. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
Han X; Wang Y; Wei J; Han W
J Hematol Oncol; 2019 Nov; 12(1):128. PubMed ID: 31783889
[TBL] [Abstract][Full Text] [Related]
14. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
[TBL] [Abstract][Full Text] [Related]
15. Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
Chen N; Li X; Chintala NK; Tano ZE; Adusumilli PS
Curr Opin Immunol; 2018 Apr; 51():103-110. PubMed ID: 29554494
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
17. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
Front Immunol; 2021; 12():638639. PubMed ID: 34177890
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
19. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
20. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]